-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merck (Merck) and Pediatric Praziquantel Consortium (Pediatric Praziquantel Consortium, PPC) recently announced that a key phase 3 clinical trial for evaluating single-dose arpraziquantel for the treatment of preschool children (3 months to 6 years old) with schistosomiasis has reached the clinical level The primary end point of cure
Schistosomiasis is a neglected tropical disease, which is a parasitic disease
Arpraziquantel is derived from praziquantel and is an orally dispersible tablet developed by PPC
Phase 3 trials were carried out by Felix Hooufère-Boigny University (Bowani University) and the Kenya Institute of Medicine, and were awarded the Global Health Innovation Technology Fund (GHIT) and European and Developing Countries Clinical Trial Partners Relationship (EDCTP) support
In this completed phase 3 trial, children aged 3 months to 6 years infected with S.
The two doses of arpraziquantel treatment showed good safety, tolerability and improved palatability in preschool children
Schistosomiasis is a chronic disease and one of the most common and destructive parasitic diseases in tropical countries
Currently, the standard care treatment for schistosomiasis is praziquantel
Arpraziquantel contains the pharmacologically active enantiomer of praziquantel
Original source: Merck Announces Positive Phase III Results for Arpraziquantel as Part of its Schistosomiasis Elimination Program
